ISV - InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite eyedrop-based drug delivery technology, as well as in the development of genetically-based technologies for the diagnosis, prognosis, and management of glaucoma. The company?s products include AzaSite (ISV-401) for the treatment of bacterial conjunctivitis and other infections of the outer eye; AzaSite Plus (ISV-502) for the treatment of blepharitis, an infection of the eyelid and common eye problems in older adults, as well as other ophthalmic infections; and AzaSite Otic (ISV-016), which is in preclinical stage is used in the treatment for ear infections. It is also developing AquaSite, which is used in the treatment of dry eye; ISV-205 that is used to treat ocular inflammation; ISV?014, a retinal delivery device for the treatment of diabetic retinopathy and macular degeneration; and OcuGene, a glaucoma genetic test. InSite Vision Incorporated has collaborative, licensing, and service agreements with Pfizer, Inc. and Pfizer Products, Inc.; Inspire Pharmaceuticals, Inc.; Cardinal Health PTS, L.L.C.; Bausch and Lomb Incorporated; Societa Industria Farmaceutica Italiana; Quest Diagnostics Incorporated; CIBA Vision Ophthalmics; UC Regents; Columbia Laboratories, Inc.; and SSP Co., Ltd. The company was founded in 1986 and is based in Alameda, California.
 |
